Empowered Patient Podcast

Dr. Shika Pappoe, CMO and COO of Carna Health is working to identify and treat chronic kidney disease earlier through screening tests. This is a breakthrough for a disease that often shows no symptoms until the damage is irreversible. Using technology and AI-powered risk prediction models to improve early detection and intervention for CKD can help slow or even halt the progression of the disease. In recent pilot programs in Bermuda and Cameroon, Carna Health found high rates of CKD and is working to connect those patients with the necessary care.

Shika explains, "Chronic kidney disease is a condition that has been growing over the years. We know that diabetes and hypertension are leading causes, and currently, CKD is the 10th leading cause of death globally. And by 2040, it's estimated that it will be the fifth cause of death. Carna is working on finding ways to identify kidney disease early so that we can slow progression and optimize the outcomes of patients around the world."

"We are seeing globally increasing rates of, again, diabetes and hypertension, the number one and two causes globally. Interestingly, communicable diseases have often been the priority in low- and middle-income countries. Still, we're seeing the rise of noncommunicable diseases such as CKD. I should say one of the other causes of this increasing epidemic is the environmental stressors, particularly heat. So. we see a lot of individuals who are working or living in very hot climates who are developing recurrent episodes of acute kidney injury, which ultimately leads to CKD. So, we have numerous causes for the increasing epidemic of CKD around the globe."

#CarnaHealth #ChronicKidneyDisease #CKD #EarlyDetectionCKD

Carna.Health

Listen to the podcast here

Dr. Shika Pappoe, CMO and COO of Carna Health is working to identify and treat chronic kidney disease earlier through screening tests. This is a breakthrough for a disease that often shows no symptoms until the damage is irreversible. Using technology and AI-powered risk prediction models to improve early detection and intervention for CKD can help slow or even halt the progression of the disease. In recent pilot programs in Bermuda and Cameroon, Carna Health found high rates of CKD and is working to connect those patients with the necessary care.

Shika explains, "Chronic kidney disease is a condition that has been growing over the years. We know that diabetes and hypertension are leading causes, and currently, CKD is the 10th leading cause of death globally. And by 2040, it's estimated that it will be the fifth cause of death. Carna is working on finding ways to identify kidney disease early so that we can slow progression and optimize the outcomes of patients around the world."

"We are seeing globally increasing rates of, again, diabetes and hypertension, the number one and two causes globally. Interestingly, communicable diseases have often been the priority in low- and middle-income countries. Still, we're seeing the rise of noncommunicable diseases such as CKD. I should say one of the other causes of this increasing epidemic is the environmental stressors, particularly heat. So. we see a lot of individuals who are working or living in very hot climates who are developing recurrent episodes of acute kidney injury, which ultimately leads to CKD. So, we have numerous causes for the increasing epidemic of CKD around the globe."

#CarnaHealth #ChronicKidneyDisease #CKD #EarlyDetectionCKD

Carna.Health

Download the transcript here

Karthik Ganesh, CEO at OnMed, is expanding access to healthcare through its CareStation, a self-contained medical pod that allows patients to receive comprehensive primary care services conveniently. The CareStation is designed to be easily deployed and operated in underserved communities, including rural areas, prisons, and foster care facilities. This scalable, hybrid approach provides a personalized examination using medical devices and cameras that allow a remote clinician to prescribe treatment and, if necessary, arrange for further actions.

Karthik explains, "The OnMed CareStation gives you the psychological comfort and the confidence of a comprehensive primary care visit. With the rapid scalability and the convenience of telemedicine, it essentially takes the best of both worlds between virtual care and traditional care while also neutralizing the inherent scalability weaknesses and experience weaknesses of both of those. This is why we look at OnMed really as a hybrid care company and the CareStation as a tech-enabled, hybrid care vehicle."

"Pretty much every day of the week without a wait, you can just walk in for care. It's cleaner than a doctor's office because, after every single visit, we use UVC lighting to clean out the CareStation. UVC has been known to essentially kill over 99.9% of viruses and bacteria inside of the CareStation. And then, finally, the third thing I would say that makes it unique is it's an extremely personalized experience. There are the reviews we've gotten back from the patients going into the CareStation, where they feel the interpersonal connection with a live clinician. Still, at the same time, they feel it's without any distractions of a doctor's office, people walking outside, the doctor coming in and out, and so on. They feel in that contained space, it's an extremely personalized and intimate conversation with the doctor, exactly as you would expect a highly personal doctor-patient relationship to be."

#OnMed #HybridCare #HealthEquity #HealthcareAccess

onmed.com

Listen to the podcast here

Karthik Ganesh, CEO at OnMed, is expanding access to healthcare through its CareStation, a self-contained medical pod that allows patients to receive comprehensive primary care services conveniently. The CareStation is designed to be easily deployed and operated in underserved communities, including rural areas, prisons, and foster care facilities. This scalable, hybrid approach provides a personalized examination using medical devices and cameras that allow a remote clinician to prescribe treatment and, if necessary, arrange for further actions.

Karthik explains, "The OnMed CareStation gives you the psychological comfort and the confidence of a comprehensive primary care visit. With the rapid scalability and the convenience of telemedicine, it essentially takes the best of both worlds between virtual care and traditional care while also neutralizing the inherent scalability weaknesses and experience weaknesses of both of those. This is why we look at OnMed really as a hybrid care company and the CareStation as a tech-enabled, hybrid care vehicle."

"Pretty much every day of the week without a wait, you can just walk in for care. It's cleaner than a doctor's office because, after every single visit, we use UVC lighting to clean out the CareStation. UVC has been known to essentially kill over 99.9% of viruses and bacteria inside of the CareStation. And then, finally, the third thing I would say that makes it unique is it's an extremely personalized experience. There are the reviews we've gotten back from the patients going into the CareStation, where they feel the interpersonal connection with a live clinician. Still, at the same time, they feel it's without any distractions of a doctor's office, people walking outside, the doctor coming in and out, and so on. They feel in that contained space, it's an extremely personalized and intimate conversation with the doctor, exactly as you would expect a highly personal doctor-patient relationship to be."

#OnMed #HybridCare #HealthEquity #HealthcareAccess

onmed.com

Download the transcript here

George Eliades, the CEO of Mythic Therapeutics a company focused on the next generation of antibody-drug conjugates, ADCs, to treat cancer. Their approach aims to expand the population of patients who can benefit from ADCs by targeting proteins expressed at low levels on cancer cells. The company's lead candidate targets the MET protein in non-small cell lung cancer cells and is designed to deliver chemotherapy more selectively and effectively to cancer cells using the FateControl ™ technology.

George explains, "We try to be different in two important ways for patients. If you think about ADCs, they've been around for a long time with the promise of bringing chemotherapy-like efficacy, but the safety of a targeted therapy because so much less chemo is being administered to the patient and that chemo is going directly, at least in theory, to the cancer cell. That was sort of the first promise. The second thing that's happened over the years is that the patients who benefit from ADCs tend to be a very small subset of patients, and those are the patients who express a very high level of the target. Generally, it's a protein on the cancer cell that the ADC binds to. And if you don't have a high level of that target expression in general, you don't benefit as much from the ADC."

"What we're trying to do is two things. Number one, we're trying to make it so more patients can benefit from ADCs and bring it to the patients who have low expressions of those proteins we're trying to target. And the second thing that we're trying to do is deliver on the initial promise. When I say that, I mean to have a drug that is very tolerable for patients but gives them the tumor shrinkage that the patient wants. Also it lets them stay on the drug without feeling terrible so they can get on with their day."

#MythicTherapeutics #ADCs #AntibodyDrugConjugate #FateControl #NSCLC #LungCancer #Oncology

mythictx.com

Listen to the podcast here

George Eliades, the CEO of Mythic Therapeutics a company focused on the next generation of antibody-drug conjugates, ADCs, to treat cancer. Their approach aims to expand the population of patients who can benefit from ADCs by targeting proteins expressed at low levels on cancer cells. The company's lead candidate targets the MET protein in non-small cell lung cancer cells and is designed to deliver chemotherapy more selectively and effectively to cancer cells using the FateControl ™ technology.

George explains, "We try to be different in two important ways for patients. If you think about ADCs, they've been around for a long time with the promise of bringing chemotherapy-like efficacy, but the safety of a targeted therapy because so much less chemo is being administered to the patient and that chemo is going directly, at least in theory, to the cancer cell. That was sort of the first promise. The second thing that's happened over the years is that the patients who benefit from ADCs tend to be a very small subset of patients, and those are the patients who express a very high level of the target. Generally, it's a protein on the cancer cell that the ADC binds to. And if you don't have a high level of that target expression in general, you don't benefit as much from the ADC."

"What we're trying to do is two things. Number one, we're trying to make it so more patients can benefit from ADCs and bring it to the patients who have low expressions of those proteins we're trying to target. And the second thing that we're trying to do is deliver on the initial promise. When I say that, I mean to have a drug that is very tolerable for patients but gives them the tumor shrinkage that the patient wants. Also it lets them stay on the drug without feeling terrible so they can get on with their day."

#MythicTherapeutics #ADCs #AntibodyDrugConjugate #FateControl #NSCLC #LungCancer #Oncology

mythictx.com

Download the transcript here

Karl Ulfers, CEO and Co-Founder of DUOS, helps older adults and their caregivers access government benefits and programs to improve the quality of life and enable aging in place. Working with Medicare Advantage and dual-eligible health plans, DUOS uses a combination of technology, generative AI, and personalized support to help patients navigate the system to apply for and receive state, Federal, and VA benefits and services. The focus is on addressing the social determinants of health and health equity, especially in rural and underserved communities.

Karl explains "It's really interesting when you study these individuals that we work with. We tend to get about 15% of a payer's population activated and using our service, which is pretty high. And the people that make up that population, it's quite interesting - 88% of them make less than $28,000 a year. They're, on average, about 74 years old. They tend to skew female versus male and value what we bring to them in terms of helping them tap into these benefits and government programs available to them. They either didn't know about or didn't know how to use them."

"We love to say that we are re-imagining the aging experience and to some of the comments where we started our conversation - we believe that we're not just creating a system of aging. We're creating a system of aging that we ourselves are going to inherit. So we're motivated by the direct impact that we can have on the older adults in our lives, as well as the impact that we can have on the system in the future for ourselves."

#DUOS #AgeTech #MedicareAdvantage #Medicare #AgingIndependently #PowerofConnections #Healthcare #SDOH #VABenefits #FederalBenefits

getduos.com

Listen to the podcast here

Karl Ulfers, CEO and Co-Founder of DUOS, helps older adults and their caregivers access government benefits and programs to improve the quality of life and enable aging in place. Working with Medicare Advantage and dual-eligible health plans, DUOS uses a combination of technology, generative AI, and personalized support to help patients navigate the system to apply for and receive state, Federal, and VA benefits and services. The focus is on addressing the social determinants of health and health equity, especially in rural and underserved communities.

Karl explains "It's really interesting when you study these individuals that we work with. We tend to get about 15% of a payer's population activated and using our service, which is pretty high. And the people that make up that population, it's quite interesting - 88% of them make less than $28,000 a year. They're, on average, about 74 years old. They tend to skew female versus male and value what we bring to them in terms of helping them tap into these benefits and government programs available to them. They either didn't know about or didn't know how to use them."

"We love to say that we are re-imagining the aging experience and to some of the comments where we started our conversation - we believe that we're not just creating a system of aging. We're creating a system of aging that we ourselves are going to inherit. So we're motivated by the direct impact that we can have on the older adults in our lives, as well as the impact that we can have on the system in the future for ourselves."

#DUOS #AgeTech #MedicareAdvantage #Medicare #AgingIndependently #PowerofConnections #Healthcare #SDOH #VABenefits #FederalBenefits

getduos.com

Download the transcript here

Dr. Ed Glynn, Chief Clinical Officer at RhythmX AI, is bridging the gap between real-world clinical data and the use of artificial intelligence. One of the key problems RhythmX is trying to solve is the cognitive burden on primary care clinicians to understand all relevant details about each patient. Using the RhythmX platform, an AI-enabled intelligent assistant sits alongside the doctor to summarize patient information, track progress, and provide recommendations to help provide more holistic, patient-centered care.

Ed explains, "Our vision is to really pioneer hyper-personalized care. We do this by enabling clinicians, specialists, and care teams to deliver the right care, at the right time for the right patient and the right channel. We do this through a very clear focus on marrying both real-world clinicians- clinicians who are out there on the front lines and see patients - with deep artificial intelligence experience. And we have a number of years in many different engineers in the background taking care of this. We believe that the synergy of these two aspects, real-world clinicians with deep artificial intelligence experience, is much greater than the sum of the two. And that's the spirit we're approaching primary care with this new tool."

"As a starting clinical officer here at RhythmX AI, I see my focus as bringing together those two worlds: the real world, the clinical world, and this artificial intelligence world. It's bridging the gap between the two of those and assuring that the two of these aspects, clinicians and artificial intelligence expertise, can sit down and decide what are the prioritized problems that are facing primary care clinicians today? How do we approach that and bring safe, trustworthy artificial intelligence as an intelligent assistant to these clinicians on the front lines? Ultimately, through this process, we champion patient safety and quality here at RhythmX AI."

#RhythmXAI #PrimaryCare #HealthAI #Healthcare #PatientCentric #ClinicianBurnout #CognitiveBurnout #PrecisionCare

rhythmx.ai

Listen to the podcast here

Dr. Ed Glynn, Chief Clinical Officer at RhythmX AI, is bridging the gap between real-world clinical data and the use of artificial intelligence. One of the key problems RhythmX is trying to solve is the cognitive burden on primary care clinicians to understand all relevant details about each patient. Using the RhythmX platform, an AI-enabled intelligent assistant sits alongside the doctor to summarize patient information, track progress, and provide recommendations to help provide more holistic, patient-centered care.

Ed explains, "Our vision is to really pioneer hyper-personalized care. We do this by enabling clinicians, specialists, and care teams to deliver the right care, at the right time for the right patient and the right channel. We do this through a very clear focus on marrying both real-world clinicians- clinicians who are out there on the front lines and see patients - with deep artificial intelligence experience. And we have a number of years in many different engineers in the background taking care of this. We believe that the synergy of these two aspects, real-world clinicians with deep artificial intelligence experience, is much greater than the sum of the two. And that's the spirit we're approaching primary care with this new tool."

"As a starting clinical officer here at RhythmX AI, I see my focus as bringing together those two worlds: the real world, the clinical world, and this artificial intelligence world. It's bridging the gap between the two of those and assuring that the two of these aspects, clinicians and artificial intelligence expertise, can sit down and decide what are the prioritized problems that are facing primary care clinicians today? How do we approach that and bring safe, trustworthy artificial intelligence as an intelligent assistant to these clinicians on the front lines? Ultimately, through this process, we champion patient safety and quality here at RhythmX AI."

#RhythmXAI #PrimaryCare #HealthAI #Healthcare #PatientCentric #ClinicianBurnout #CognitiveBurnout #PrecisionCare

rhythmx.ai

Download the transcript here